Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

3(42.9%)

7Total

Phase 2(4)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01576471Phase 2Completed

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

Role: lead

NCT01520558Phase 1Unknown

CNDO-109-AANK for AML in First Complete Remission (CR1)

Role: lead

NCT01953354Phase 2Terminated

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

Role: collaborator

NCT02140112Phase 2Terminated

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder

Role: lead

NCT02011269Phase 2Withdrawn

TSO for Plaque Psoriasis

Role: lead

NCT01836939Phase 1Completed

Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis

Role: collaborator

NCT01434693Phase 1Completed

Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease

Role: lead

All 7 trials loaded